Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

Abstract: Provided is use of an NGF antibody in CIPN pain. In particular, the NGF antibody blocks the interaction of nerve growth factors (NGF) with receptors thereof, and thus can treat and/or prevent chemotherapy-induced peripheral neuropathy (CIPN) pain.

Abstract: Provided are an intermediate (connexon and load combination) for preparing an antibody-drug conjugate (ADC), a preparation method therefor, and the use thereof. The connexon and load combination has a structure as represented by formula I. Formula I can be used for coupling highly hydrophobic compound loads, such as paclitaxel (PTX’), and a prepared ADC molecule has good hydrophilicity and thermal stability and can achieve a higher drug-to-antibody ratio.

Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, where-in R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

Abstract: A virtual reality guide hypnosis speech processing method and apparatus, wherein the method comprises: performing a text analysis for a hypnosis guide language, so as to obtain text hierarchical information of the hypnosis guide language; performing a speech analysis for the hypnosis guide language, so as to obtain speech rhythm information of the hypnosis guide language; searching a hypnosis speech library for corresponding speech units, according to the text hierarchical information and the speech rhythm information of the hypnosis guide language, the hypnosis speech library storing speech units generated according to corpus data recorded by a user's susceptible person; synthesizing found speech units into hypnosis speech data; and synthesizing the hypnosis speech data with a virtual reality hypnosis scene, and outputting a virtual reality guide hypnosis speech. The present disclosure can improve the user's hypnosis susceptibility and optimize the hypnosis effect.

Abstract: The invention provides a method and a device for seeing through an obstruction based on smart glasses, and a computer-readable storage medium, the method comprising: acquiring a first image of user's view by smart glasses and recognizing an obstruction image in the first image; acquiring a second image of the user's view by at least one image acquisition device; replacing the obstruction image in the first image with portion of the second image that corresponds to the obstruction image, which are spliced to generate an unobstruction image of the user's view. In the invention, the obstruction image in the first image is replaced with a portion of the second image that corresponds to the obstruction image, which can achieve seeing through an obstruction.

Abstract: The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.

Abstract: The invention provides a method and a device for seeing through an obstruction based on smart glasses, and a computer-readable storage medium, the method comprising: acquiring a first image of user's view by smart glasses and recognizing an obstruction image in the first image; acquiring a second image of the user's view by at least one image acquisition device; replacing the obstruction image in the first image with portion of the second image that corresponds to the obstruction image, which are spliced to generate an unobstruction image of the user's view. In the invention, the obstruction image in the first image is replaced with a portion of the second image that corresponds to the obstruction image, which can achieve seeing through an obstruction.

Abstract: The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: A virtual reality guide hypnosis speech processing method and apparatus, wherein the method comprises: performing a text analysis for a hypnosis guide language, so as to obtain text hierarchical information of the hypnosis guide language; performing a speech analysis for the hypnosis guide language, so as to obtain speech rhythm information of the hypnosis guide language; searching a hypnosis speech library for corresponding speech units, according to the text hierarchical information and the speech rhythm information of the hypnosis guide language, the hypnosis speech library storing speech units generated according to corpus data recorded by a user's susceptible person; synthesizing found speech units into hypnosis speech data; and synthesizing the hypnosis speech data with a virtual reality hypnosis scene, and outputting a virtual reality guide hypnosis speech. The present disclosure can improve the user's hypnosis susceptibility and optimize the hypnosis effect.

Abstract: The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula I, and methods for using compounds of Formula I for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.

Abstract: The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

Abstract: The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

Abstract: The present invention concerns compounds of formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.